Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
Viatris Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.94 |
52 Week High | US$13.62 |
52 Week Low | US$8.74 |
Beta | 1.14 |
1 Month Change | -9.75% |
3 Month Change | 10.25% |
1 Year Change | 24.90% |
3 Year Change | -14.10% |
5 Year Change | -56.46% |
Change since IPO | 1,847.26% |
Recent News & Updates
Recent updates
Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
Mar 02From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Jan 12Viatris stock rises amid potential plans for €3B sale of European OTC assets
Oct 11Take These Broken Wings And Learn To Fly Again Viatris
Sep 25Viatris: 5% Dividend Yield Is A Threat For Investors
Sep 06Viatris: Products, Profitability And Pipeline - The Keys To Success
Aug 20Viatris declares $0.12 dividend
Aug 08Viatris: A Spinoff To Own
Aug 02Viatris extends decline to reach 52-week low
Jul 22Viatris: Guidance Likely To Be Cut With Q2 Results
Jul 15Viatris: The Market Is Not Buying It - Downtrend Since 2015
May 09Viatris: 3 Things That Can Break The Bull Thesis In 2022
Apr 20I No Longer Think Viatris Is A Buy
Apr 08Viatris: Takeaways From Management At The Raymond James Conference
Mar 10My Investment Thesis On Viatris Remains Intact After The Sale Of The Biosimilars Assets
Feb 28Shareholder Returns
VTRS | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -0.6% | 2.2% | 0.2% |
1Y | 24.9% | 25.5% | 28.1% |
Return vs Industry: VTRS matched the US Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: VTRS underperformed the US Market which returned 28.1% over the past year.
Price Volatility
VTRS volatility | |
---|---|
VTRS Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTRS has not had significant price volatility in the past 3 months.
Volatility Over Time: VTRS's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1961 | 38,000 | Scott Smith | https://www.viatris.com |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Viatris Inc. Fundamentals Summary
VTRS fundamental statistics | |
---|---|
Market cap | US$14.05b |
Earnings (TTM) | US$54.70m |
Revenue (TTM) | US$15.43b |
259.2x
P/E Ratio0.9x
P/S RatioIs VTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VTRS income statement (TTM) | |
---|---|
Revenue | US$15.43b |
Cost of Revenue | US$8.69b |
Gross Profit | US$6.73b |
Other Expenses | US$6.68b |
Earnings | US$54.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.046 |
Gross Margin | 43.64% |
Net Profit Margin | 0.35% |
Debt/Equity Ratio | 88.5% |
How did VTRS perform over the long term?
See historical performance and comparison